lasmiditan

FDA Drug Profile — Reyvow

Drug Details

Generic Name
lasmiditan
Brand Names
Reyvow
Application Number
NDA211280
Sponsor
Lilly del Caribe, Inc.
NDC Codes
4
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
LASMIDITAN

Indications and Usage

1 INDICATIONS AND USAGE REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.